It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Amide proton transfer (APT)-weighted chemical exchange saturation transfer (CEST) imaging is a recent MRI technique making its way into clinical application. In this work, we investigated whether APT-weighted CEST imaging can provide reproducible measurements across scan sessions and scanners. Within-session, between-session and between scanner reproducibility was calculated for 19 healthy volunteers and 7 patients with a brain tumor on two 3T MRI scanners. The APT-weighted CEST effect was evaluated by calculating the Lorentzian Difference (LD), magnetization transfer ratio asymmetry (MTRasym), and relaxation-compensated inverse magnetization transfer ratio (MTRREX) averaged in whole brain white matter (WM), enhancing tumor and necrosis. Within subject coefficient of variation (COV) calculations, Bland–Altman plots and mixed effect modeling were performed to assess the repeatability and reproducibility of averaged values. The group median COVs of LD APT were 0.56% (N = 19), 0.84% (N = 6), 0.80% (N = 9) in WM within-session, between-session and between-scanner respectively. The between-session COV of LD APT in enhancing tumor (N = 6) and necrotic core (N = 3) were 4.57% and 5.67%, respectively. There were no significant differences in within session, between session and between scanner comparisons of the APT effect. The COVs of LD and MTRREX were consistently lower than MTRasym in all experiments, both in healthy tissues and tumor. The repeatability and reproducibility of APT-weighted CEST was clinically acceptable across scan sessions and scanners. Although MTRasym is simple to acquire and compute and sufficient to provide robust measurement, it is beneficial to include LD and MTRREX to obtain higher reproducibility for detecting minor signal difference in different tissue types.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Erasmus MC, Department of Radiology & Nuclear Medicine, Rotterdam, The Netherlands (GRID:grid.5645.2) (ISNI:0000 0004 0459 992X); Brain Tumour Centre, Erasmus MC Cancer Institute, Rotterdam, The Netherlands (GRID:grid.508717.c) (ISNI:0000 0004 0637 3764)
2 King’s College London, Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764)
3 Erasmus MC, Department of Radiology & Nuclear Medicine, Rotterdam, The Netherlands (GRID:grid.5645.2) (ISNI:0000 0004 0459 992X); Erasmus MC-University Medical Centre Rotterdam, Department of Medical Oncology, Rotterdam, The Netherlands (GRID:grid.5645.2) (ISNI:0000 0004 0459 992X)
4 Erasmus MC, Department of Radiology & Nuclear Medicine, Rotterdam, The Netherlands (GRID:grid.5645.2) (ISNI:0000 0004 0459 992X)
5 Erasmus MC, Department of Radiology & Nuclear Medicine, Rotterdam, The Netherlands (GRID:grid.5645.2) (ISNI:0000 0004 0459 992X); Medical Delta, Delft, The Netherlands (GRID:grid.5645.2)
6 Erasmus MC, Department of Radiology & Nuclear Medicine, Rotterdam, The Netherlands (GRID:grid.5645.2) (ISNI:0000 0004 0459 992X); Brain Tumour Centre, Erasmus MC Cancer Institute, Rotterdam, The Netherlands (GRID:grid.508717.c) (ISNI:0000 0004 0637 3764); Medical Delta, Delft, The Netherlands (GRID:grid.508717.c)